Summary Of 15 anti-CEA monoclonal antibodies, the first 8 were reactive only with CEA, while the remaining 7 antibodies reacted with epitopes commonly expressed on CEA and the normal cross-reacting antigen, NCA. Separate and distinct, conformation-dependent (i.e. susceptible to reduction and alkylation), CEA-associated epitopes were identified using antibodies 1, 2 and 3. Antibodies 4 to 7 defined a series of conformation-independent epitopes which were topographically closely related on the CEA molecule. Antibody number 8 reacted with a separate determinant found on CEA but not NCA, and this also was resistant to reduction and alkylation.
Carcinoembryonic antigen (CEA) is a carbohydrate-rich glycoprotein, often expressed in tumours of the human gastro-intestinal tract, and which consists of a single polypeptide chain with about 40 N-linked oligosaccharide chains (Rogers, 1983; Chandrasekaran et al., 1983) . Purified CEA preparations exhibit microheterogeneity which has been attributed to variations in its associated oligosaccharides (Coligan et al., 1973; Primus et al., 1983) and frequently inimunochemical procedures have been employed to define the structure of CEA. Monoclonal antibodies have proved to be particularly valuable in this respect and epitopes specifically expressed on CEA molecules have been clearly distinguished from other epitopes commonly found on CEA molecules and immunologically-related glycoproteins associated with certain normal tissues (Kuroki et al., 1984; Blaszczyk et al., 1984; Haggarty et al., 1986) .
In the present investigation, a panel of 15 anti-CEA monoclonal antibodies have been used to probe the epitope structure of CEA molecules and to establish a basis for the selection of reagents for antibody directed targeting to tumours of both radioisotopes for immunoscintigraphy and cytotoxic drugs for therapy.
Materials and methods

Monoclonal antibodies
Monoclonal antibodies 1 to 15 were prepared by conventional hybridoma technology by which the spleen cells from immunized BALB/c mice were fused with cells of the mouse myeloma, P3NS1 (Kohler & Milstein, 1975) . Mice were immunized with purified CEA, colorectal tumour subcellular membranes or viable colonic tumour cells and antibodies were selected for their reactivity with CEA (Price et al., 1985; Durrant et al., 1986) . All antibodies were the products of separate fusions with the exception of antibodies 6 and 7, and antibodies 12 and 13. The immunoglobulin class and subclass of antibodies was determined as previously described (Price & Baldwin, 1984) . Monoclonal antibodies were purified from ascitic fluids or from hybridoma tissue culture supernatants by their binding to and elution from Sepharose-protein A (Pharmacia, Uppsala, Sweden).
Antigen preparations CEA was purified from hepatic metastases from primary colonic adenocarcinoma according to the method of Krupey et al., (1972) and NCA was isolated from human spleen as previously described (Blaszczyk et al., 1984; Price et al., 1985) . The purity of both antigen preparations was examined by sodium dodecyl sulphate polyacrylamide gel electrophoresis. CEA gave a single diffuse band migrating with an apparent molecular weight of 180 kD while NCA preparations showed a single band at 60 kD.
Chemical treatment of CEA CEA was reduced and alkylated with iodoacetamide according to Krantz and Laferte (1983) . CEA (0.25mg ml -1) was dissolved in 0.7 M Tris-HCl, pH 8.8, containing 0.2% SDS. After flushing the vial with nitrogen, 15 mM dithiothreitol was added, and it was sealed and heated at 100°C for 5 min. After cooling to room temperature, 50 mm iodoacetamide was added and the reaction mixture was kept in the dark for 30 min. Reagents were then removed by passage through a column of Sephadex G25 (Pharmacia, Uppsala, Sweden) equilibrated with PBS, pH 7.3. CEA preparations were also treated with NalO4 solutions (Westwood & Thomas, 1975 incubation for 1 to 2 h at room temperature, the wells were aspirated and washed 4 times. '251-labelled, affinity purified F(ab')2 fragments of rabbit anti-mouse Ig were added at -105cpmlOpl-l per well (radioiodination of this reagent was performed using the chloramine T procedure of Jensenius and Williams (1974) using 500 jiCi 1251 per 25 jug protein). Incubation was continued for 1 to 2 h at room temperature. The wells were aspirated, then washed 6 times, after which the radioactivity in each well was determined.
The non-specific binding of antibodies to 'PBS-coated' and 'BSA/RbS-blocked' wells was determined and the values obtained were subtracted from those determined with antigen-coated, BSA/RbS-blocked and antibody treated wells.
Competitive inhibition of 12 5I-labelled antibody binding Monoclonal antibodies were radiolabelled using the chloramine T procedure (Jensenius & Williams, 1974) (Table I) .
All antibodies were strongly reactive with CEA in the radioisotopic antiglobulin assay (Table I) . Antibodies 1 to 8 failed to react with the normal cross-reacting antigen, NCA, whereas antibodies 9 to 16 bound to NCA. Within this latter group, antibody 15, and to a lesser extent, antibody 14 were preferentially reactive with CEA and antibody 9 appeared more reactive with NCA.
Further subgrouping of the epitopes defined by these antibodies was achieved by examining the retention of their Table I Monoclonal antibody reactivity with activity to heat-and chemically-treated CEA capacity to bind to CEA after antigen modification using various treatments. As shown in Table I , the epitopes for each of the 15 antibodies were largely resistant to the effects of heat treatment at 100°C for 5min, indicative of their overall stability. However, when CEA was reduced and alkylated, it was clear that 4 of the antibodies no longer bound to the antigen (i.e. antibodies numbered 1, 2, 3 and 9 -Table I) while the binding of the remaining antibodies to modified antigen was unaffected. The epitopes defined by the first three CEA-reactive antibodies (1, 2 and 3) and the NCA-reactive antibody number 9, thus require the retention of conformation for full expression of their antibody binding activity. The susceptibility of the various epitopes to modification with 0.005 M NaIO4 revealed less marked differences between these antibodies. The epitope of antibody number 3 was evidently the most resistant to NaIO4 treatment while that defined by the antibody number 9 was extremely susceptible to inactivation. While antibodies 13 and 15 were not examined in this particular assay, it was determined that their capacity to react with periodate-treated CEA (treated in solution, rather than adsorbed to plastic) was similar to that of antibodies 10, 11, 12 and 14. Discrimination between the various epitopes in their capacity to bind their respective antibodies, was progressively lost in samples exposed to increasing concentrations of periodate, this being indicative of increasing modification of the protein core as well as alteration to carbohydrate moieties.
Competitive inhibition of 12I5-labelled antibody to CEA The 15 monoclonal antibodies were tested for their capacity to inhibit the binding of radiolabelled antibodies to CEA. Unlabelled antibodies as inhibitors were tested as purified antibodies (at concentrations of 1, 3 and 10igml-1) and/or as hybridoma supernatants (at dilutions of neat, 1/3 and 1/10). An example of the data obtained is illustrated in Figure 1 . The level of binding of each radiolabelled antibody to CEA in the absence of an inhibitor was set at 100% and the binding of labelled antibody in the presence of the inhibitor was related to this figure. Some antibodies were only available as purified preparations (e.g. antibody 2 in Figure 1 ) while with others, such as antibody 1, only small quantities of hybridoma supernatant were available. Nevertheless, when purified antibodies and supernatants were assayed as inhibitors in parallel tests (e.g. using antibodies 3 to 6 in Figure 1) Figure 2 is a diagrammatic representation of the inhibitory reactions described in Table II . Initially, for the preparation of this figure, each antibody-defined epitope was described by a circle. Antibodies showing reactivity only with CEA, and those cross-reactive with NCA and CEA (Table I) are indicated by the stippled and open circles respectively. Overlapping between pairs of circles was drawn to indicate an inhibitory interaction between the respective antibodies.
Discussion
As shown in Figure 2 , antibodies 1 and 2 react with distinct, conformation-dependent epitopes on the CEA molecule; similarly, antibody 3 reacts with a CEA-associated, conformation-dependent (and relatively periodate-resistant- Table I ) epitope, but from the 'cold' antibody inhibition tests in Figure 1 and Table II , the epitope of antibody 3 is closer to the main group of epitopes than is antibody 1 or 2. The antibodies 4 to 7 define conformation-independent (i.e. a resistance to reduction and alkylation - Table I) CEAspecific epitopes which appear to be topographically close to each other -there are several cross-inhibitory interactions between these antibodies so that it is probable that they react with an immunodominant area of the CEA molecule. Antibody number 8, the only IgM antibody (Table I) , defines an epitope which is unrelated to those reactive with the other CEA-binding antibodies, 1 to 7.
Of the antibodies which were reactive with both CEA and NCA, antibody number 9 was unique -its epitope was conformation-dependent and very sensitive to periodate (Table I) . Unlabelled antibody 9 failed to inhibit the binding of all of the labelled antibodies tested with the exception of antibodies 3 and 4, although these inhibitory reactions were very weak (Table II) . The remaining antibodies 10 to 15 were all resistant to reduction and alkylation, and in each combination of labelled antibody and inhibitor tested, all antibodies in this group were cross-inhibitory (Table II) . Thus, these antibodies appear to belong to a group which react with an immunodominant area of the CEA molecule which is shared between CEA and NCA. Each of these considerations have been taken into account in developing the model in Figure 2 .
The number of epitopes on the CEA molecule would appear to be limited. A maximum number of 10 CEAspecific epitopes was identified using polyclonal antisera (Sundblad et al., 1976) . More recently, using a panel of 18 monoclonal antibodies, 12 different epitopes were distinguished, including 7 which were CEA-specific (Haggarty et al., 1986) . In similar investigations, Kuroki et al. (1984) Figure 2 ).
The present findings provide a rational basis for selecting anti-CEA antibodies of appropriate specificity as well as antibody class or subclass for a number of potential clinical applications. These include their use in immunodiagnostic tests for circulating CEA and for the localization of tumours in patients using radiolabelled antibodies (Begent, 1985; Mach et al., 1981) . Such antibodies may be further employed T I T T T . T T as vehicles to target cytotoxic drugs or toxins to tumour deposits and the results described assist in the formulation of 'cocktails' of anti-CEA antibodies which would be additive rather than inhibitory in their binding to CEA.
